Publication: Rosiglitazone attenuates liver inflammation in a rat model of nonalcoholic steatohepatitis
No Thumbnail Available
Date
2007
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
SPRINGER
Abstract
Rosiglitazone is an insulin-sensitizing agent. We aimed to assess the effects of rosiglitazone on a methionine- and choline-deficient diet (MCDD) model of nonalcoholic steatohepatitis (NASH) in rats. Wistar rats were fed either MCDD or a control diet in the 4-week induction study; they were given saline or 4 mg/kg/day rosiglitazone. After the induction study period, the rats were divided into four groups and fed MCDD or given a control diet for an additional 8 weeks and received saline or rosiglitazone. Serum and tissue samples were obtained. Rosiglitazone improved inflammation in NASH and improved ALT, alkaline phosphatase, and interleukin-6 levels in the induction study and interleukin-1 beta, interleukin-6, and tumor necrosis factor-alpha levels in the treatment study. Our preliminary study is the first to show the anti-inflammatory effects of rosiglitazone in NASH. Rosiglitazone's effect on cytokines may be a key mechanism of its anti-inflammatory effect in NASH.
Description
Keywords
rosiglitazone, insulin resistance, nonalcoholic fatty liver disease, oral glucose tolerance test, reactive oxygen species, cytokine, interleukin, tumor necrosis factor, GAMMA LIGAND ROSIGLITAZONE, STELLATE CELL ACTIVATION, CHOLINE-DEFICIENT DIET, INSULIN SENSITIVITY, HEPATIC STEATOSIS, REACTIVE OXYGEN, RECEPTOR-GAMMA, TROGLITAZONE, METHIONINE, TRIGLYCERIDE